Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENV-101 (Taladegib) in Idiopathic Pulmonary Fibrosis
NCT04968574Phase 2Completed
- Sponsor
- Endeavor BioMedicines
- Start
- Aug 2021
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 2 trial of taladegib in idiopathic pulmonary fibrosis (IPF), sponsored by Endeavor BioMedicines. Started Aug 2021; status: completed.
02
Drugs
taladegib
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT04968574.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04968574.